Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Amortization - Intangibles (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Amortization - Intangibles for 11 consecutive years, with $526000.0 as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 42.89% to $526000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 23.68% year-over-year, with the annual reading at $3.7 million for FY2025, 0.0% changed from the prior year.
  • Amortization - Intangibles for Q4 2025 was $526000.0 at Aytu Biopharma, up from $444000.0 in the prior quarter.
  • The five-year high for Amortization - Intangibles was $1.5 million in Q3 2021, with the low at $444000.0 in Q3 2025.
  • Average Amortization - Intangibles over 5 years is $1.1 million, with a median of $924000.0 recorded in 2023.
  • The sharpest move saw Amortization - Intangibles increased 3.43% in 2022, then plummeted 51.79% in 2025.
  • Over 5 years, Amortization - Intangibles stood at $1.5 million in 2021, then decreased by 20.4% to $1.2 million in 2022, then dropped by 23.37% to $918000.0 in 2023, then increased by 0.33% to $921000.0 in 2024, then tumbled by 42.89% to $526000.0 in 2025.
  • According to Business Quant data, Amortization - Intangibles over the past three periods came in at $526000.0, $444000.0, and $921000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.